abstract |
The present invention relates to the detection of MAGE-A9 in a biological sample and to the diagnosis, prevention and treatment of MAGE-A9-associated aberrant cell growth, through the targeting of the MAGE-A9 polypeptide and/or polynucleotide. Diagnosis is accomplished by examining or monitoring cells for perturbations in MAGE-A9 expression. Prevention and treatment are accomplished by administering to a subject MAGE-A9 as a protein or a fragment thereof or under form of a DNA expression vector, as well as by administering to a subject a MAGE-A9 gene product-binding agent. Compositions and commercial kits are also provided. |